Table 1.
Univariate and multivariate regression analysis of the association between overall survival and clinical characteristics and key driver mutations in KRAS mutated PDAC patients from the TCGA cohort
| Characteristics | Total (N) | HR(95% CI) Univariate analysis | P-value Univariate analysis | HR(95% CI) Multivariate analysis | P-value Multivariate analysis |
|---|---|---|---|---|---|
| Age | 116 | 1.019 (0.997–1.042) | 0.087 | 1.015 (0.992–1.039) | 0.195 |
| Sex | 116 | ||||
| Male | 69 | Reference | |||
| Female | 47 | 1.093 (0.685–1.745) | 0.708 | ||
| AJCC Stage | 116 | ||||
| Stage I | 8 | Reference | |||
| Stage II | 101 | 1.114 (0.404–3.073) | 0.834 | ||
| Stage III | 3 | 1.352 (0.245–7.456) | 0.729 | ||
| Stage IV | 4 | 1.127 (0.251–5.067) | 0.876 | ||
| KRAS | 116 | ||||
| G12V | 33 | Reference | Reference | ||
| G12D | 48 | 1.748 (0.984–3.107) | 0.057 | 1.715 (0.965–3.048) | 0.066 |
| G12R | 25 | 1.062 (0.508–2.224) | 0.872 | 1.070 (0.511–2.242) | 0.858 |
| Q61 | 8 | 2.954 (1.151–7.585) | 0.024 | 2.712 (1.048–7.020) | 0.040 |
| other | 2 | 5.574 (1.260–24.665) | 0.024 | 4.906 (1.098–21.924) | 0.037 |
| TP53 | 116 | ||||
| Mut | 90 | Reference | |||
| Wild | 26 | 0.688 (0.375–1.263) | 0.227 | ||
| CDKN2A | 116 | ||||
| Mut | 33 | Reference | |||
| Wild | 83 | 0.887 (0.527–1.493) | 0.652 | ||
| SMAD4 | 116 | ||||
| Mut | 32 | Reference | |||
| Wild | 84 | 1.281 (0.750–2.189) | 0.365 | ||
| TMB | 116 | 1.111 (0.734–1.682) | 0.618 | ||
| MSI | 116 | 1.021 (0.853–1.222) | 0.820 |